264 related articles for article (PubMed ID: 29474461)
1. Distinct susceptibility of HIV vaccine vector-induced CD4 T cells to HIV infection.
Auclair S; Liu F; Niu Q; Hou W; Churchyard G; Morgan C; Frahm N; Nitayaphan S; Pitisuthithum P; Rerks-Ngarm S; Kimata JT; Soong L; Franchini G; Robb M; Kim J; Michael N; Hu H
PLoS Pathog; 2018 Feb; 14(2):e1006888. PubMed ID: 29474461
[TBL] [Abstract][Full Text] [Related]
2. Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1.
Benlahrech A; Harris J; Meiser A; Papagatsias T; Hornig J; Hayes P; Lieber A; Athanasopoulos T; Bachy V; Csomor E; Daniels R; Fisher K; Gotch F; Seymour L; Logan K; Barbagallo R; Klavinskis L; Dickson G; Patterson S
Proc Natl Acad Sci U S A; 2009 Nov; 106(47):19940-5. PubMed ID: 19918060
[TBL] [Abstract][Full Text] [Related]
3. Preferential infection of human Ad5-specific CD4 T cells by HIV in Ad5 naturally exposed and recombinant Ad5-HIV vaccinated individuals.
Hu H; Eller MA; Zafar S; Zhou Y; Gu M; Wei Z; Currier JR; Marovich MA; Kibuuka HN; Bailer RT; Koup RA; Robb ML; Michael NL; Kim JH; Ratto-Kim S
Proc Natl Acad Sci U S A; 2014 Sep; 111(37):13439-44. PubMed ID: 25197078
[TBL] [Abstract][Full Text] [Related]
4. Early CD4+ T Cell Responses Are Associated with Subsequent CD8+ T Cell Responses to an rAd5-Based Prophylactic Prime-Boost HIV Vaccine Strategy.
Lhomme E; Richert L; Moodie Z; Pasin C; Kalams SA; Morgan C; Self S; De Rosa SC; Thiébaut R
PLoS One; 2016; 11(4):e0152952. PubMed ID: 27124598
[TBL] [Abstract][Full Text] [Related]
5. HIV Susceptibility of human antigen-specific CD4 T cells in AIDS pathogenesis and vaccine response.
Hu H; Liu F; Kim J; Ratto-Kim S
Expert Rev Vaccines; 2016 Jun; 15(6):709-17. PubMed ID: 26814372
[TBL] [Abstract][Full Text] [Related]
6. Adenovirus-based HIV-1 vaccine candidates tested in efficacy trials elicit CD8+ T cells with limited breadth of HIV-1 inhibition.
Hayes PJ; Cox JH; Coleman AR; Fernandez N; Bergin PJ; Kopycinski JT; Nitayaphan S; Pitisuttihum P; de Souza M; Duerr A; Morgan C; Gilmour JW
AIDS; 2016 Jul; 30(11):1703-12. PubMed ID: 27088318
[TBL] [Abstract][Full Text] [Related]
7. Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates.
García-Arriaza J; Perdiguero B; Heeney J; Seaman M; Montefiori DC; Labranche C; Yates NL; Shen X; Tomaras GD; Ferrari G; Foulds KE; McDermott A; Kao SF; Roederer M; Hawkins N; Self S; Yao J; Farrell P; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo A; Weiss D; Lee C; Kibler K; Jacobs B; Asbach B; Wagner R; Ding S; Pantaleo G; Esteban M
J Virol; 2015 Aug; 89(16):8525-39. PubMed ID: 26041302
[TBL] [Abstract][Full Text] [Related]
8. Modulation of Vaccine-Induced CD4 T Cell Functional Profiles by Changes in Components of HIV Vaccine Regimens in Humans.
Pissani F; Schulte B; Eller MA; Schultz BT; Ratto-Kim S; Marovich M; Thongcharoen P; Sriplienchan S; Rerks-Ngarm S; Pitisuttithum P; Esser S; Alter G; Robb ML; Kim JH; Michael NL; Streeck H
J Virol; 2018 Dec; 92(23):. PubMed ID: 30209165
[TBL] [Abstract][Full Text] [Related]
9. Priming and Activation of Inflammasome by Canarypox Virus Vector ALVAC via the cGAS/IFI16-STING-Type I IFN Pathway and AIM2 Sensor.
Liu F; Niu Q; Fan X; Liu C; Zhang J; Wei Z; Hou W; Kanneganti TD; Robb ML; Kim JH; Michael NL; Sun J; Soong L; Hu H
J Immunol; 2017 Nov; 199(9):3293-3305. PubMed ID: 28947539
[TBL] [Abstract][Full Text] [Related]
10. Recombinant vector-induced HIV/SIV-specific CD4+ T lymphocyte responses in rhesus monkeys.
Sun Y; Santra S; Buzby AP; Mascola JR; Nabel GJ; Letvin NL
Virology; 2010 Oct; 406(1):48-55. PubMed ID: 20667574
[TBL] [Abstract][Full Text] [Related]
11. Heterologous HIV-based lentiviral/adenoviral vectors immunizations result in enhanced HIV-specific immunity.
Asefa B; Korokhov N; Lemiale F
Vaccine; 2010 Apr; 28(20):3617-24. PubMed ID: 20051277
[TBL] [Abstract][Full Text] [Related]
12. Adenovirus vector-specific T cells demonstrate a unique memory phenotype with high proliferative potential and coexpression of CCR5 and integrin alpha4beta7.
Chakupurakal G; Onion D; Cobbold M; Mautner V; Moss PA
AIDS; 2010 Jan; 24(2):205-10. PubMed ID: 19864932
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of ALVAC-HIV vCP1521 in infants of HIV-1-infected women in Uganda (HPTN 027): the first pediatric HIV vaccine trial in Africa.
Kaleebu P; Njai HF; Wang L; Jones N; Ssewanyana I; Richardson P; Kintu K; Emel L; Musoke P; Fowler MG; Ou SS; Jackson JB; Guay L; Andrew P; Baglyos L; Cao H;
J Acquir Immune Defic Syndr; 2014 Mar; 65(3):268-77. PubMed ID: 24091694
[TBL] [Abstract][Full Text] [Related]
14. Long-term mucosal T cell activation and homing phenotypes in recipients of an Ad5-vectored HIV vaccine.
Curlin ME; Shao J; Diaz G; Edlefsen PT; Novak RM; Mayer KH; Allen M; Morgan C; Maenza J; Buchbinder S; Keefer MC; Rosa SC; Corey L; Duerr A;
Vaccine; 2020 Aug; 38(36):5814-5821. PubMed ID: 32680773
[TBL] [Abstract][Full Text] [Related]
15. MVA-nef induces HIV-1-specific polyfunctional and proliferative T-cell responses revealed by the combination of short- and long-term immune assays.
Kutscher S; Allgayer S; Dembek CJ; Bogner JR; Protzer U; Goebel FD; Erfle V; Cosma A
Gene Ther; 2010 Nov; 17(11):1372-83. PubMed ID: 20535218
[TBL] [Abstract][Full Text] [Related]
16. Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, host-range-restricted canarypox vector (ALVAC) carrying the HIV-1MN env gene.
Egan MA; Pavlat WA; Tartaglia J; Paoletti E; Weinhold KJ; Clements ML; Siliciano RF
J Infect Dis; 1995 Jun; 171(6):1623-7. PubMed ID: 7769304
[TBL] [Abstract][Full Text] [Related]
17. A double-blind randomized phase I clinical trial targeting ALVAC-HIV vaccine to human dendritic cells.
Eller MA; Slike BM; Cox JH; Lesho E; Wang Z; Currier JR; Darden JM; Polonis VR; Vahey MT; Peel S; Robb ML; Michael NL; Marovich MA
PLoS One; 2011; 6(9):e24254. PubMed ID: 21949699
[TBL] [Abstract][Full Text] [Related]
18. Decreased pre-existing Ad5 capsid and Ad35 neutralizing antibodies increase HIV-1 infection risk in the Step trial independent of vaccination.
Cheng C; Wang L; Gall JG; Nason M; Schwartz RM; McElrath MJ; DeRosa SC; Hural J; Corey L; Buchbinder SP; Nabel GJ
PLoS One; 2012; 7(4):e33969. PubMed ID: 22496775
[TBL] [Abstract][Full Text] [Related]
19. Immune-correlates analysis of an HIV-1 vaccine efficacy trial reveals an association of nonspecific interferon-γ secretion with increased HIV-1 infection risk: a cohort-based modeling study.
Huang Y; Duerr A; Frahm N; Zhang L; Moodie Z; De Rosa S; McElrath MJ; Gilbert PB
PLoS One; 2014; 9(11):e108631. PubMed ID: 25369172
[TBL] [Abstract][Full Text] [Related]
20. Baseline Ad5 serostatus does not predict Ad5 HIV vaccine-induced expansion of adenovirus-specific CD4+ T cells.
Hutnick NA; Carnathan DG; Dubey SA; Makedonas G; Cox KS; Kierstead L; Ratcliffe SJ; Robertson MN; Casimiro DR; Ertl HC; Betts MR
Nat Med; 2009 Aug; 15(8):876-8. PubMed ID: 19620962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
